The Filings Report

Solventum Corporation

SOLVNYSECIK 1964738Healthcare / Medical Devicesfiscal year ends December14 quarters since 2023

Revenue, Q2 FY2026
$2.2B
+2.2% on Q2 FY2025
Net income
$92M
+2.2% on Q2 FY2025
Free cash flow
$144M
+144.1% on Q2 FY2025
Diluted EPS
$0.53
+3.9% on Q2 FY2025
Revenue, TTM
$8.3B
trailing four quarters
Net margin, TTM
17.3%
net income $1.4B
Free cash flow, TTM
−$118M
$209M less $327M capex
Cash and equivalents
$403M
long-term debt $4.6B, Jun 30, 2026
Shares, 12-month change
−1.8%
170M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$13.8B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Solventum Corporation reported revenue of $2.2B, +2.2% on Q2 FY2025, and net income of $92M (+2.2%). Operating margin was 8.2%. Free cash flow, operating cash flow less capital expenditures, was $144M ($227M less $83M). Diluted earnings per share were $0.53.

The last 14 quarters

Q1 FY2023 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
$0$1B$2B$3BQ1'23, Revenue: $2.0BQ1'23, Net income: $293MQ1'23Q2'23, Revenue: $2.1BQ2'23, Net income: $321MQ2'23Q3'23, Revenue: $2.1BQ3'23, Net income: $460MQ3'23Q4'23, Revenue: $2.0BQ4'23, Net income: $272MQ4'23Q1'24, Revenue: $2.0BQ1'24, Net income: $237MQ1'24Q2'24, Revenue: $2.1BQ2'24, Net income: $89MQ2'24Q3'24, Revenue: $2.1BQ3'24, Net income: $122MQ3'24Q4'24, Revenue: $2.1BQ4'24, Net income: $31MQ4'24Q1'25, Revenue: $2.1BQ1'25, Net income: $137MQ1'25Q2'25, Revenue: $2.2BQ2'25, Net income: $90MQ2'25Q3'25, Revenue: $2.1BQ3'25, Net income: $1.3BQ3'25Q4'25, Revenue: $2.0BQ4'25, Net income: $63MQ4'25Q1'26, Revenue: $2.0BQ1'26, Net income: $13MQ1'26Q2'26, Revenue: $2.2BQ2'26, Net income: $92MQ2'26$0$1B$2B$3BQ1'23, Revenue: $2.0BQ1'23, Net income: $293MQ2'23, Revenue: $2.1BQ2'23, Net income: $321MQ2'23Q3'23, Revenue: $2.1BQ3'23, Net income: $460MQ4'23, Revenue: $2.0BQ4'23, Net income: $272MQ4'23Q1'24, Revenue: $2.0BQ1'24, Net income: $237MQ2'24, Revenue: $2.1BQ2'24, Net income: $89MQ2'24Q3'24, Revenue: $2.1BQ3'24, Net income: $122MQ4'24, Revenue: $2.1BQ4'24, Net income: $31MQ4'24Q1'25, Revenue: $2.1BQ1'25, Net income: $137MQ2'25, Revenue: $2.2BQ2'25, Net income: $90MQ2'25Q3'25, Revenue: $2.1BQ3'25, Net income: $1.3BQ4'25, Revenue: $2.0BQ4'25, Net income: $63MQ4'25Q1'26, Revenue: $2.0BQ1'26, Net income: $13MQ2'26, Revenue: $2.2BQ2'26, Net income: $92MQ2'26

Net income losses drawn in red.

Free cash flow
−$400M−$200M$0$200M$400M$600MQ1'23, Free cash flow: $444MQ1'23Q2'23, Free cash flow: $295MQ2'23Q3'23, Free cash flow: $427MQ3'23Q4'23, Free cash flow: $459MQ4'23Q1'24, Free cash flow: $340MQ1'24Q2'24, Free cash flow: $297MQ2'24Q3'24, Free cash flow: $76MQ3'24Q4'24, Free cash flow: $92MQ4'24Q1'25, Free cash flow: −$80MQ1'25Q2'25, Free cash flow: $59MQ2'25Q3'25, Free cash flow: −$21MQ3'25Q4'25, Free cash flow: $32MQ4'25Q1'26, Free cash flow: −$273MQ1'26Q2'26, Free cash flow: $144MQ2'26−$400M−$200M$0$200M$400M$600MQ1'23, Free cash flow: $444MQ2'23, Free cash flow: $295MQ2'23Q3'23, Free cash flow: $427MQ4'23, Free cash flow: $459MQ4'23Q1'24, Free cash flow: $340MQ2'24, Free cash flow: $297MQ2'24Q3'24, Free cash flow: $76MQ4'24, Free cash flow: $92MQ4'24Q1'25, Free cash flow: −$80MQ2'25, Free cash flow: $59MQ2'25Q3'25, Free cash flow: −$21MQ4'25, Free cash flow: $32MQ4'25Q1'26, Free cash flow: −$273MQ2'26, Free cash flow: $144MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$3B$5B$8B$10BQ1'23Q2'23Q3'23Q4'23, Cash and equivalents: $194MQ4'23, Long-term debt: $0Q4'23Q1'24, Cash and equivalents: $996MQ1'24, Long-term debt: $8.3BQ1'24Q2'24, Cash and equivalents: $897MQ2'24, Long-term debt: $8.3BQ2'24Q3'24, Cash and equivalents: $772MQ3'24, Long-term debt: $7.8BQ3'24Q4'24, Cash and equivalents: $762MQ4'24, Long-term debt: $7.8BQ4'24Q1'25, Cash and equivalents: $534MQ1'25, Long-term debt: $7.8BQ1'25Q2'25, Cash and equivalents: $492MQ2'25, Long-term debt: $7.8BQ2'25Q3'25, Cash and equivalents: $1.6BQ3'25, Long-term debt: $5.1BQ3'25Q4'25, Cash and equivalents: $878MQ4'25, Long-term debt: $5.0BQ4'25Q1'26, Cash and equivalents: $561MQ1'26, Long-term debt: $4.6BQ1'26Q2'26, Cash and equivalents: $403MQ2'26, Long-term debt: $4.6BQ2'26$0$3B$5B$8B$10BQ2'23Q4'23, Cash and equivalents: $194MQ4'23, Long-term debt: $0Q4'23Q1'24, Cash and equivalents: $996MQ1'24, Long-term debt: $8.3BQ2'24, Cash and equivalents: $897MQ2'24, Long-term debt: $8.3BQ2'24Q3'24, Cash and equivalents: $772MQ3'24, Long-term debt: $7.8BQ4'24, Cash and equivalents: $762MQ4'24, Long-term debt: $7.8BQ4'24Q1'25, Cash and equivalents: $534MQ1'25, Long-term debt: $7.8BQ2'25, Cash and equivalents: $492MQ2'25, Long-term debt: $7.8BQ2'25Q3'25, Cash and equivalents: $1.6BQ3'25, Long-term debt: $5.1BQ4'25, Cash and equivalents: $878MQ4'25, Long-term debt: $5.0BQ4'25Q1'26, Cash and equivalents: $561MQ1'26, Long-term debt: $4.6BQ2'26, Cash and equivalents: $403MQ2'26, Long-term debt: $4.6BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Solventum Corporation income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 8, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue2,2092,0071,9982,0962,1612,0702,0752,082+2.2%
Cost of revenue—————————
Gross profit1,2861,0971,0271,1351,1751,1141,1191,165+9.4%
Research and development178189175183189193199189−5.8%
Selling, general and administrative927827759780772769784701+20.1%
Operating income181811241,690214152136275−15.4%
Other income (expense)(9)(4)(15)(5)(8)(11)(16)(1)−12.5%
Pretax income10816581,5141033813167+4.9%
Income tax153(5)24813(99)(17)45+15.4%
Net income9213631,2669013731122+2.2%
Diluted EPS ($)0.530.07—7.220.510.78—0.70+3.9%
Diluted shares (millions)173176—175175175—174—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Solventum Corporation balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 8, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents4035618781,642492534762772−18.1%
Short-term investments—————————
Total current assets3,7413,5833,8594,4073,2083,0533,2493,354+16.6%
Total assets14,24314,09714,29413,97315,07414,52714,45714,745−5.5%
Total current liabilities3,6633,3463,1362,9382,6202,5662,7032,904+39.8%
Long-term debt4,5734,5755,0355,1377,8157,8137,8107,809−41.5%
Total liabilities9,4439,1289,2458,98711,42911,26511,49811,553−17.4%
Stockholders’ equity4,8004,9695,0494,9863,6453,2622,9593,192+31.7%
Shares outstanding (millions)170173173173173173173173—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Solventum Corporation cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 8, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow227(189)957616929219169+34.3%
Capital expenditures8384639711010912793−24.5%
Free cash flow (CFO − capex)144(273)32(21)59(80)9276+144.1%
Depreciation and amortization133135117121122129150133+9.0%
Share repurchases28867——00———
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 27, 2026.

Income statement

Solventum Corporation income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed May 10, 2024FY2022ended Dec 31, 2022filed May 10, 2024
Revenue8,3258,2548,1978,130
Cost of revenue————
Gross profit4,4514,5934,6934,695
Research and development739775758767
Selling, general and administrative3,0802,7822,2992,235
Operating income2,1811,0361,6921,693
Other income (expense)(39)(64)(25)(1)
Pretax income1,7136051,6671,692
Income tax157127321349
Net income1,5564791,3461,343
Diluted EPS ($)8.882.767.797.78
Diluted shares (millions)175174173173

Balance sheet

Solventum Corporation balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed May 10, 2024FY2022ended Dec 31, 2022filed May 10, 2024
Cash and equivalents878762194—
Short-term investments————
Total current assets3,8593,2492,519—
Total assets14,29414,45713,943—
Total current liabilities3,1362,7031,728—
Long-term debt5,0357,8100—
Total liabilities9,24511,4982,277—
Stockholders’ equity5,0492,95911,66611,742
Shares outstanding (millions)173173173—

Cash flow statement

Solventum Corporation cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed May 10, 2024FY2022ended Dec 31, 2022filed May 10, 2024
Operating cash flow3691,1851,9151,679
Capital expenditures379380290251
Free cash flow (CFO − capex)(10)8051,6251,428
Depreciation and amortization489555561578
Share repurchases————
Dividends paid————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$100K
1 purchases by 1 insider; officers and directors $100K
Sold, twelve months
$0
0 sales by 0 insiders; officers and directors $0

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 1, 2026Hanson Bryan CChief Executive Officer, Directoroption exercise67,261——211,983Sep 3, 2026
Sep 1, 2026Hanson Bryan CChief Executive Officer, Directortax withholding26,468$90.95$2M185,515Sep 3, 2026
May 13, 2026Gomez Tammy LChief Human Resources Officeroption exercise3,960$0.00—15,030May 15, 2026
May 13, 2026Gomez Tammy LChief Human Resources Officertax withholding1,668$74.41$124K13,362May 15, 2026
May 13, 2026McMillan Wayde D.Chief Financial Officeroption exercise9,503$0.00—53,041May 15, 2026
May 13, 2026McMillan Wayde D.Chief Financial Officertax withholding4,404$74.41$328K48,637May 15, 2026
May 13, 2026Harrington Paul SChief Supply Chain Officeroption exercise3,960$0.00—22,130May 15, 2026
May 13, 2026Harrington Paul SChief Supply Chain Officertax withholding1,678$74.41$125K20,452May 15, 2026
May 13, 2026Wilcox Mary TChief Accounting Officeroption exercise2,376$0.00—7,632May 15, 2026
May 13, 2026Wilcox Mary TChief Accounting Officertax withholding728$74.41$54K6,904May 15, 2026
May 13, 2026Kirberger Marcela A.Chief Legal Affairs Officeroption exercise4,488$0.00—15,492May 15, 2026
May 13, 2026Kirberger Marcela A.Chief Legal Affairs Officertax withholding1,952$74.41$145K13,540May 15, 2026
May 13, 2026Hanson Bryan CChief Executive Officer, Directoroption exercise34,315$0.00—158,225May 15, 2026
May 13, 2026Hanson Bryan CChief Executive Officer, Directortax withholding13,503$74.41$1M144,722May 15, 2026
May 13, 2026Landucci AmyChief Information Officeroption exercise4,422$0.00—41,905May 15, 2026
May 13, 2026Landucci AmyChief Information Officertax withholding2,017$74.41$150K39,888May 15, 2026
Apr 30, 2026Wendell Amy McBrideDirectoroption exercise3,403$0.00—10,422May 1, 2026
Apr 30, 2026Weiland John HDirectoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026Mily ElizabethDirectoroption exercise3,403$0.00—9,009May 1, 2026
Apr 30, 2026Wilson Darryl L.Directoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026May Karen JDirectoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026Harris Bernard A JrDirectoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026Eisenberg Glenn ADirectoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026Edwards Shirley AnnDirectoroption exercise3,403$0.00—8,947May 1, 2026
Apr 30, 2026DeVore Susan D.Directoroption exercise3,403$0.00—8,947May 1, 2026

Full insider history for Solventum Corporation, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held SOLV in their latest 13F filing, through August 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded SOLV by quarter.

FundManagerQuarterValueSharesWeightMove
Trian Fund ManagementNelson PeltzQ2 2026$635M8M15.02%held

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
SOLVENTUM CORPORATION, CIK 1964738 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/SOLV.json